reolysin: Clinical Trials

16 trials of reolysin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 active not recruiting, 2 withdrawn, 1 unknown. 16 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 11, Active not recruiting 2, Withdrawn 2, Unknown 1
Phase 23Active not recruiting 2, Withdrawn 1

Follow reolysin: new trials by email Literature Review of reolysin trials Research Report on reolysin

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase 1 / Phase 2Active not recruitingUniversity of Southern California102022-10-072026-05-13
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel - Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified
Phase 1 / Phase 2Active not recruitingOncolytics Biotech1222021-10-272026-05-19
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
Pelareorep - Advanced or Metastatic Breast Cancer
Phase 1CompletedAdlai Nortye Biopharma Co., Ltd.152021-10-112023-11-22
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
Carfilzomib, Dexamethasone, Nivolumab - Recurrent Plasma Cell Myeloma
Phase 1CompletedEmory University232018-10-242023-10-06
REO13 Melanoma With of Without GM-CSF
Reolysin, GM-CSF - Melanoma, Cancer of Skin
Phase 1 / Phase 2WithdrawnUniversity of Leeds2017-10-012018-05-04
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma
Lenalidomide or Pomalidomide, REOLYSIN - Multiple Myeloma
Phase 1UnknownUniversity of Leeds42017-06-052020-01-22
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
REOLYSIN®, Gemcitabine, Cisplatin - Muscle-invasive Transitional Cell Carcinoma of the Bladder
Phase 1WithdrawnOncolytics Biotech2017-02-282017-03-07
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
REOLYSIN®, Chemotherapy, Gemcitabine - Pancreatic Adenocarcinoma
Phase 1CompletedOncolytics Biotech112015-12-012018-09-13
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase 1CompletedUniversity of Southern California142015-08-212023-08-14
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus - Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor
Phase 1CompletedMayo Clinic62015-06-212023-04-24
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis - Anemia, Recurrent Multiple Myeloma
Phase 1CompletedNational Cancer Institute (NCI)122014-12-092024-05-17
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Diagnostic Laboratory Biomarker Analysis, Wild-type Reovirus - Light Chain Deposition Disease, Refractory Plasma Cell Myeloma
Phase 1CompletedNational Cancer Institute (NCI)122012-04-012015-04-15
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
REOLYSIN®, Irinotecan, Leucovorin - KRAS Mutant Metastatic Colorectal Cancer
Phase 1CompletedOncolytics Biotech362010-12-012018-12-19
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
wild-type reovirus, cyclophosphamide, laboratory biomarker analysis - Unspecified Childhood Solid Tumor, Protocol Specific
Phase 1CompletedNational Cancer Institute (NCI)262010-12-012014-05-13
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
Laboratory Biomarker Analysis, Wild-type Reovirus - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Phase 1CompletedNational Cancer Institute (NCI)702008-04-012016-08-08
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
REOLYSIN® - Malignant Glioma
Phase 1CompletedOncolytics Biotech182006-07-012014-10-02

Conditions studied

Multiple Myeloma (6)  ·  Neoplasms (3)  ·  Glioma (2)  ·  Anemia (1)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Diffuse Intrinsic Pontine Glioma (1)  ·  Fallopian Tube Neoplasms (1)  ·  Glioblastoma (1)  ·  Medulloblastoma (1)  ·  Melanoma (1)  ·  Neuroectodermal Tumors, Primitive (1)  ·  Oligodendroglioma (1)  ·  Ovarian Neoplasms (1)

Sponsors

Oncolytics Biotech (5)  ·  National Cancer Institute (NCI) (4)  ·  University of Leeds (2)  ·  University of Southern California (2)  ·  Adlai Nortye Biopharma Co., Ltd. (1)  ·  Emory University (1)  ·  Mayo Clinic (1)

Countries

United States (11)  ·  Canada (1)  ·  China (1)  ·  Germany (1)  ·  United Kingdom (1)

Top investigators

Craig C Hofmeister (1)  ·  Craig Hofmeister (1)  ·  Craig Hofmeister, MD, MPH (1)  ·  David Cohn (1)  ·  E. Anders Kolb (1)  ·  Gordon Cook (1)  ·  James M Markert, MD (1)  ·  Kevin Kelly, MD (1)  ·  Kevin R Kelly, MD (1)  ·  Richard Bram (1)  ·  Sukeshi Patel Arora, MD (1)  ·  Wei Li, M.D. (1)

Results publications

PMID 37812476, PMID 39828738

NIH funding

P30CA016058 (3), U01CA076576 (3), P30CA014089 (2), P30CA015083 (1), P30CA138292 (1), U01CA097452 (1), UM1CA186691 (1), UM1CA186712 (1)